Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VTB reported for January-February by IFRS

3/27/24 VTBR

Softline opened additional Noventiq GDR exchange window

3/27/24 SOFL

Whoosh reported for 2023 by IFRS

3/27/24 WUSH

Samolet plans to pay at least ₽5 billion in dividends

3/27/24 SMLT

Trust sold a part of the preferred shares of Russneft

3/27/24 RNFT

Sistema approved a new div policy

3/27/24 AFKS

Stavropolenergosbyt reported for 2023 by RAS

3/26/24 STSB

brainbox.VC became a Skolkovo resident

3/26/24 OTCI

Saratovenergo reported for 2023 according to IFRS

3/26/24 SARE

RussNeft reports for 2023 by IFRS

3/26/24 RNFT